SGLT2 inhibitors for the treatment of type 2 diabetes: relaxing List 2 conditions
The National Health Care Institute has carried out a substantive assessment of whether the existing list 2 conditions for SGLT2 inhibitors could be relaxed. This is a group assessment. The present question was whether patients who do not achieve their HbA1c target values despite a therapy including an optimally titrated basal-bolus insulin regimen would benefit from the addition of SGLT2 inhibitors. The National Health Care Institute has now completed its assessment, after being advised by the Scientific Advisory Board.
Advice
The National Health Care Institute has concluded that for the treatment of diabetes mellitus type 2, there is no added therapeutic value of the addition of SGLT2 inhibitors to an optimally titrated basal-bolus insulin regimen in comparison to the addition of placebo, if insufficient regulation is achieved by means of an optimally adjusted basal-bolus insulin regimen.
As a result, the National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) not to alter the existing List 2 conditions.
This report is a summary of recommendations by the National Health Care Institute. The original text of this excerpt is in Dutch.